Why Farbe Firma is the Top Manufacturer of Colistimethate Sodium for Injection
- Maulik Sudani
- 2 days ago
- 10 min read
Last Updated: July 5, 2026
TL;DR: Colistimethate Sodium for Injection - a sterile powder for reconstitution containing colistimethate sodium (colistin methanesulfonate, CMS), the inactive prodrug of colistin (polymyxin E) that hydrolyses in the body to active colistin, a polymyxin antibiotic that binds the lipid A of the lipopolysaccharide in the Gram-negative outer membrane and disrupts membrane permeability, supplied commonly as a 1 million IU (about 80 mg) vial reconstituted with water for injection for intravenous infusion, intramuscular injection or nebulisation - is the last-resort antibiotic clinicians use against multidrug-resistant Gram-negative organisms such as Pseudomonas aeruginosa, Acinetobacter baumannii and carbapenem-resistant Klebsiella pneumoniae. Because a potency-critical, prodrug peptide antibiotic dosed in International Units is dissolved from a dry powder and infused into a vein, each vial must deliver a sterile, correctly potent, low-moisture powder that reconstitutes to a clear solution, with the colistimethate assay and colistin content, water content by Karl Fischer, reconstitution time and clarity, particulate and endotoxin, aseptic-process sterility assurance and verified container-closure integrity all mattering to potency and safety. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Colistimethate Sodium for Injection at our Gujarat, India facility and supplies it to intensive-care, infectious-disease, respiratory and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Polymyxin antibiotic (colistin prodrug) - colistimethate sodium is the methanesulfonate prodrug of colistin (polymyxin E), a cyclic polypeptide that binds the lipid A of the lipopolysaccharide in the Gram-negative outer membrane, displaces the stabilising calcium and magnesium ions and disrupts membrane permeability so the cell dies, and Colistimethate Sodium for Injection (a sterile powder reconstituted to a 1 million IU / about 80 mg dose for intravenous infusion, intramuscular injection or nebulisation) demands a correctly potent, low-moisture, sterile powder in every vial.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated aseptic dry-powder compounding and vial filling with cross-contamination controls, control of the colistimethate assay and colistin content by HPLC, water content by Karl Fischer, reconstitution time and solution clarity, particulate and endotoxin, media-fill-validated aseptic-process sterility assurance, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, media-fill and aseptic-process-validation data, sterilisation and container-closure data, forced-degradation data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile polymyxin-antibiotic powder-for-injection contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets with International-Unit-to-milligram dosing tables, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Colistimethate Sodium for Injection Demands a Premium Manufacturer
Colistimethate Sodium for Injection has moved from a reserve agent to a frontline weapon against multidrug-resistant Gram-negative infection across many markets. It is the antibiotic a clinician turns to when carbapenems and other first-line agents have failed or cannot be used - when the pathogen is a multidrug-resistant aerobic Gram-negative organism such as Pseudomonas aeruginosa, Acinetobacter baumannii or a carbapenem-resistant Klebsiella pneumoniae or other Enterobacterales - in ventilator-associated pneumonia, bloodstream infection and complicated urinary-tract infection, and, given by nebulisation, in the chronic Pseudomonas colonisation of cystic fibrosis. Colistimethate sodium is itself an inactive prodrug: colistin methanesulfonate is the less-toxic sulfomethylated derivative of colistin, or polymyxin E, and once in the body it hydrolyses back to active colistin, which binds the lipid A of the lipopolysaccharide in the Gram-negative outer membrane, displaces the calcium and magnesium ions that stabilise it and disrupts membrane permeability until the cell dies. What makes the parenteral form distinctive is that it is a genuine last-line therapy dosed in International Units, given to some of the sickest patients in the hospital, so the prescriber depends on a vial whose potency and sterility are beyond doubt.
That clinical reality places real demands on the manufacturer. Colistimethate Sodium for Injection is presented not as a ready-to-use solution but as a sterile powder for reconstitution, because colistimethate sodium hydrolyses in water and cannot be supplied as a stable aqueous solution - it must be filled and sealed dry, then reconstituted with water for injection immediately before use. Its strength is expressed in International Units, most commonly a 1 million IU vial (roughly 80 mg of colistimethate sodium), with 2 million IU and 4.5 million IU vials and, in some markets, vials labelled in milligrams of colistin base activity. That three-way unit system - International Units, milligrams of colistimethate sodium and milligrams of colistin base activity - is a documented source of serious dosing errors, so the label, leaflet and carton must state the units unambiguously and carry a clear conversion table. As a prodrug peptide antibiotic, potency is the defining attribute: the assay must confirm the colistimethate content and the composition of the polymyxin E components, both controlled by validated HPLC, because an under-strength last-line antibiotic risks treatment failure in a patient who has no other options. The powder must be low in moisture, verified by Karl Fischer titration, so that it stays stable through shelf life and reconstitutes cleanly; reconstitution must be gentle to avoid frothing and must give a clear solution within a defined time. Because a dry powder cannot be terminally sterilised, sterility is achieved by aseptic processing - sterilising-grade filtration of the bulk followed by aseptic filling under ISO Class 5, validated by media fills - with endotoxin held very low, which is essential in critically ill patients, and container-closure integrity assured for the sealed vial. Choosing a Colistimethate Sodium for Injection manufacturer that treats assay and colistin-content accuracy, moisture control and aseptic sterility assurance as core disciplines is what protects the patient at the point of care.
What Sets a World-Class Colistimethate Sodium for Injection Manufacturer Apart
A world-class manufacturer of Colistimethate Sodium for Injection invests in three areas that weaker suppliers underfund: precise, validated control of the colistimethate assay and colistin content by HPLC - confirming the labelled International Units and the composition of the polymyxin E components a prodrug peptide antibiotic must deliver; rigorous aseptic-processing and cross-contamination control, because a dry-powder antibiotic that cannot be terminally sterilised depends entirely on validated aseptic filling, routine media fills and strict segregation; and tender-ready dossier support, including the aseptic-process-validation, moisture and stability data, for a last-line antibiotic procured through intensive-care, infectious-disease and ministry-of-health channels. It starts with the raw materials - pharmacopoeial colistimethate sodium of controlled potency, water content and impurity profile - each sourced from qualified, audited suppliers with full assay, colistin-content and endotoxin data and certificates of analysis verified by the receiving laboratory before the material enters production. Because the value of the product is a precise, stable, fully potent, sterile dose of a last-resort antibiotic, the assay, the colistin content, the endotoxin and the sterility assurance are treated as central evidence rather than supporting annexes.
Compounding and filling then have to build - and defend - a correctly potent, low-moisture, sterile powder. Because colistimethate sodium hydrolyses in water, there is no wet hold: where a solution step is used it is sterilising-grade filtered and processed quickly and cold, and the product is otherwise handled as a dry sterile powder throughout. The colistimethate is filled into glass vials under ISO Class 5 conditions in a low-humidity environment that protects the moisture specification, and the vials are stoppered and sealed under aseptic conditions validated by regular media fills, because a dry powder cannot be terminally sterilised. Filled units are 100 % inspected for fill, closure and any particulate or cosmetic defect; in-process and release testing confirm the colistimethate assay and the delivered International Units, the colistin-component profile by HPLC, water content by Karl Fischer, the reconstitution time and clarity of the reconstituted solution, the pH of the reconstituted solution, visible and sub-visible particulate matter, uniformity of the filled mass, and that endotoxin is held well within limits so the reconstituted solution is safe for intravenous, intramuscular or nebulised use. Because the product is a potency-critical, aseptically filled prodrug, the assay, the colistin content and the moisture are confirmed on the finished vial, so the powder that leaves the plant reconstitutes to the same fully potent, clear, in-specification solution the specification requires - with no loss of potency and no out-of-limit degradation in the vial across shelf life.
Quality Systems Behind Every Colistimethate Sodium for Injection
Every Farbe Firma Colistimethate Sodium for Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of colistimethate and colistin content against reference standards with confirmation of the delivered International Units, control of related substances, water content by Karl Fischer, the reconstitution time and clarity of the reconstituted solution, the pH of the reconstituted solution, uniformity of the filled mass, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the sealed vial. Certificates of analysis are issued with full traceability back to each colistimethate lot, the primary-packaging lot and the qualified person responsible for release. Because the product is an aseptically filled dry-powder antibiotic whose clinical value depends on delivered potency, the assay, the colistin content and the moisture are qualified across the process so the powder's stability is demonstrated rather than simply assumed.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated aseptic dry-powder filling with routine media fills, sterilising-grade filtration with filter-integrity testing, low-humidity powder handling with cleaning validation and cross-contamination controls, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because a last-line antibiotic given to critically ill patients must deliver its full labelled potency to overcome resistant organisms and to avoid the under-dosing that drives failure and further resistance, we treat the assay, the colistin content, the moisture, the endotoxin and the fill uniformity as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated conditions, with the assay, colistin content and moisture followed across the study, so the powder stays in specification across the labelled shelf life and the reconstitution and storage instructions on the label are supported by real data.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Colistimethate Sodium for Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad antibiotic, anti-infective and critical-care portfolio. For Colistimethate Sodium for Injection specifically, we supply the polymyxin antibiotic as a sterile powder for reconstitution in 1 million IU vials, together with 2 million IU and 4.5 million IU presentations and milligram-of-colistin-base-activity formats, under WHO-GMP conditions, with country-specific strengths, clear International-Unit and milligram labelling, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the assay, colistin-content, aseptic-process-validation, moisture and container-closure data package - ready to hand for registration and tender qualification. Buyers evaluating Colistimethate Sodium for Injection can request the assay, colistin-content and accelerated-stability summaries up front, which is often the deciding technical evidence for a last-line antibiotic in hospital-formulary and ministry-of-health review, since it is the confirmed potency of a fully active antibiotic and a validated aseptic sterility assurance that separate a dependable colistimethate from an unreliable one.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability data, media-fill and aseptic-process-validation reports, moisture and container-closure reports, forced-degradation packages, and translated package inserts and artwork - including the essential International-Unit-to-milligram conversion table, the reconstitute-gently-and-infuse instruction, the directions for nebulised use where that presentation is offered, and the caution to monitor kidney function - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Colistimethate Sodium for Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the aseptic dry-powder compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through colistimethate sourcing and potency control, the prodrug-to-colistin relationship and the International-Unit, milligram-colistimethate and milligram-colistin-base-activity unit conventions, the design of a low-moisture, aseptically filled dry-powder antibiotic, the assay and colistin-component strategy by HPLC, aseptic-process validation and media fills, reconstitution behaviour and solution clarity, endotoxin control for critically ill patients, container-closure integrity and shelf-life choices in real detail. For a last-line antibiotic where assay accuracy, sterility and stability directly govern potency and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Colistimethate Sodium for Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Colistimethate Sodium for Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated aseptic dry-powder compounding and vial filling with cross-contamination controls, sterilising-grade filtration, media-fill-validated aseptic filling, 100 % inspection and continuous environmental monitoring.
Which strengths and presentations of Colistimethate Sodium for Injection do you supply?
Our polymyxin antibiotic is available as a sterile powder for reconstitution containing colistimethate sodium (colistin methanesulfonate), commonly as 1 million IU (about 80 mg) vials, with 2 million IU and 4.5 million IU vials and milligram-of-colistin-base-activity presentations available. It is reconstituted with water for injection for intravenous infusion, intramuscular injection or nebulisation. Custom strengths, fill formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Colistimethate Sodium for Injection mainly used for?
Colistimethate Sodium for Injection is used to treat serious infections caused by multidrug-resistant aerobic Gram-negative bacteria - including Pseudomonas aeruginosa, Acinetobacter baumannii and carbapenem-resistant Klebsiella pneumoniae and other Enterobacterales - such as ventilator-associated pneumonia, bloodstream infection and complicated urinary-tract infection, and, by nebulisation, chronic Pseudomonas colonisation in cystic fibrosis. It is a prodrug (colistimethate sodium) that hydrolyses in the body to active colistin, is dosed in International Units, and requires monitoring of kidney function. Farbe Firma verifies the assay, colistin content, water content, reconstitution and endotoxin at release so each vial delivers a fully potent, sterile powder.
Can Farbe Firma support country-specific registrations for Colistimethate Sodium for Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability data, media-fill and aseptic-process-validation data, related-substance and forced-degradation packages, and translated package inserts and artwork - including the International-Unit-to-milligram conversion table - for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Colistimethate Sodium for Injection contract manufacturing?
MOQs vary by strength, fill format, label complexity and dossier requirements. For our sterile powder-for-injection vial presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments